Phenotypic and Genotypic Detection of Biofilm Formation and Efflux Pump Activity in Multi-drug Re… (NCT07541690) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Phenotypic and Genotypic Detection of Biofilm Formation and Efflux Pump Activity in Multi-drug Resistant Klebsiella Pneumoniae
100 participantsStarted 2026-04
Plain-language summary
1. Sample: urine, pus and sputum samples.
2. Culture: the samples will be inoculated on the MacConkey agar and subcultured on eosine methylene blue agar.
3. Identification of isolates will be done by:
* Colony morphology.
* Gram staining.
* Biochemical reactions: including Indole, Methyl red, Voges-Proskauer, and Citrate utilization (IMViC) tests.
4. Antimicrobial susceptibility testing of the isolates will be performed using the Kirby-Bauer method (disc diffusion method) using Muller Hinton agar according to the Clinical and Laboratory Standards Institute (CLSI 2025) guidelines for selected groups of antibiotics.
5. Phenotypic detection of biofilm formation by the microtitre plate method.
6. Phenotypic detection of efflux pump activity by ethidium bromide-agar cartwheel method.
7. Detection of biofilm genes (fimH-1, mrkA, and mrkD) by conventional PCR.
8. Detection of efflux pump genes (acrAB, tolC, and mdtk) by conventional PCR.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:1-Age and sex range: any age and any sex. 2-Clinical setting: hospital-acquired infections. 3-Single pathogen focus. 4-MDR K. pneumoniae which develop resistance to at least one agent from three or more antibiotic classes.
\-
Exclusion Criteria:1-Recent antibiotics : Use within 48-72 hours before enrollment.
2-Mixed infections.
\-
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Prevelace of biofilm formation genes in MDR Klebsiella pneumonea isolates (%)